Free tool
FAERS Monitor: Hernexeos
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219042 or its brand name (Hernexeos, Zongertinib). Reports on generic versions are filed under their own applications.
Reports
167
Serious
120
72% of reports
Hospitalization
42
Death reported
23
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea45
- disease progression25
- malignant neoplasm progression21
- metastases to central nervous system13
- rash11
- nausea10
- hepatic function abnormal9
- death8
- decreased appetite8
- dyspnoea5
- pleural effusion5
- blood creatinine increased4
- cytopenia4
- meningitis4
- metastases to liver4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 2 |
| 2025 | 21 |
| 2026 | 144 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,992 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| metastases to central nervous systemSignal | 13 | 127.1 | 75.4 | 1,502 |
| meningitisSignal | 4 | 75.5 | 28.7 | 224 |
| cytopeniaSignal | 4 | 41.2 | 15.6 | 119 |
| hepatic function abnormalSignal | 9 | 30.4 | 16.1 | 228 |
| metastases to liverSignal | 4 | 28.7 | 10.9 | 81 |
| disease progressionSignal | 25 | 26.6 | 18.5 | 594 |
| malignant neoplasm progressionSignal | 21 | 25.8 | 17.3 | 479 |
| pleural effusionSignal | 5 | 10.3 | 4.4 | 33 |
| diarrhoeaSignal | 45 | 8.8 | 6.8 | 312 |
| blood creatinine increasedSignal | 4 | 7.7 | 2.9 | 17 |
| decreased appetiteSignal | 8 | 4.3 | 2.2 | 18 |
| rashSignal | 11 | 3.2 | 1.8 | 15 |
| nausea | 10 | 1.6 | 0.9 | 2 |
| death | 8 | 1.2 | 0.6 | 0 |
| dyspnoea | 5 | 1.1 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.